In collaboration with Unither Pharmaceuticals
Date
September 24th, 2025
Time
11 AM to 11:45 AM (CET)
Topic
From Formulation to Market: Accelerate Your Injectable Journey with Blow-Fill-Seal
Description
This webinar explores how Blow-Fill-Seal (BFS) technology can accelerate the development and delivery of injectable drugs and vaccines — from early formulation to large-scale distribution. By combining unmatched sterility, flexible formats like Euroject®, and high cold chain resilience, BFS offers a compelling alternative to pre-filled syringes and multidose vials. You’ll discover Unither’s co-development approach, how it supports biologics and field-ready devices, and what performance data says about BFS under extreme conditions.
Learning outcomes:
- Understand BFS technology in the context of global vaccine and biologics needs;
- Learn how BFS compares to other delivery formats (PFS, multidose) across critical criteria;
- Explore real-world BFS applications and data on temperature-sensitive biologics;
- Discover the Euroject® platform and its potential for LMICs;
- Learn how Unither supports faster, safer, and leaner product journeys.
Speaker
1. Name
Mr. Alexandre Fontayne
Alexandre Fontayne, PhD, has worked for Unither Pharmaceuticals as Chief Scientific Officer for biological products since 2021 and is deeply involved in the development of the Euroject device. He received his PhD in Biological Science at Université Paris Sud (Paris, France) and has more than 20 years of experience in research and development, including 13 years at LFB Biotechnology working on drug design and bioproduction of biologics, including ublituximab. Dr Fontayne is co-author of 28 scientific articles and holds 12 patents.
He contributes to the training of students and employees in drug design, chemistry, manufacturing and controls activities and subcontracting.
